Athenex Inc (NASDAQ:ATNX) Short Interest Update

Athenex Inc (NASDAQ:ATNX) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 5,684,800 shares, a growth of 5.1% from the April 15th total of 5,410,100 shares. Approximately 15.8% of the company’s stock are short sold. Based on an average daily trading volume, of 379,900 shares, the days-to-cover ratio is presently 15.0 days.

Shares of NASDAQ ATNX traded down $0.09 during trading on Friday, reaching $19.98. 281,989 shares of the company traded hands, compared to its average volume of 733,606. The firm’s 50 day moving average price is $17.25. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.22 and a quick ratio of 1.85. The stock has a market capitalization of $1.34 billion, a PE ratio of -13.88 and a beta of -0.29. Athenex has a 52-week low of $9.38 and a 52-week high of $21.11.

Athenex (NASDAQ:ATNX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.08). The company had revenue of $25.31 million for the quarter, compared to analysts’ expectations of $19.55 million. Athenex had a negative net margin of 189.86% and a negative return on equity of 96.55%. As a group, equities research analysts forecast that Athenex will post -1.73 EPS for the current fiscal year.

In other news, Director Stephanie A. Davis acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were bought at an average cost of $18.00 per share, with a total value of $180,000.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $180,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Life Sciences Maste Perceptive acquired 130,000 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were purchased at an average cost of $17.94 per share, for a total transaction of $2,332,200.00. The disclosure for this purchase can be found here. Insiders bought a total of 318,210 shares of company stock worth $5,111,581 over the last ninety days. Insiders own 18.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA boosted its holdings in shares of Athenex by 913,400.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 9,135 shares of the company’s stock valued at $112,000 after acquiring an additional 9,134 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of Athenex during the 4th quarter valued at about $147,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Athenex during the 1st quarter valued at about $158,000. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Athenex by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,245 shares of the company’s stock valued at $181,000 after acquiring an additional 11,125 shares during the last quarter. Finally, Private Advisor Group LLC boosted its holdings in shares of Athenex by 6.2% during the 4th quarter. Private Advisor Group LLC now owns 17,091 shares of the company’s stock valued at $217,000 after acquiring an additional 991 shares during the last quarter. 31.21% of the stock is currently owned by hedge funds and other institutional investors.

ATNX has been the topic of several recent analyst reports. CIBC cut their price objective on shares of Rocky Mountain Dealerships from C$10.50 to C$10.00 in a research report on Thursday, May 2nd. BidaskClub downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. SunTrust Banks increased their price objective on shares of Accenture to $180.00 and gave the company a “hold” rating in a research report on Friday, March 29th. They noted that the move was a valuation call. Oppenheimer cut their price objective on shares of Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating on shares of in a research report on Tuesday, June 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Athenex has an average rating of “Buy” and a consensus price target of $22.17.

About Athenex

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Further Reading: Purposes and Functions of the Federal Reserve

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.